The designation of psoriatic arthritis (PsA) as a clinical entity goes back less than forty years 1 . Taxonomically, PsA belongs to the spondyloarthropathiesÐa group of conditions whose characteristics include familial clustering, association with HLA-B27, predominant axial and peripheral asymmetrical joint involvement, negative rheumatoid factor and extra-articular signs 2±4 . Support for the view that PsA is a spondyloarthropathy has emerged from imaging studies. Using fat-suppressed T2-weighted magnetic resonance imaging, McGonagle and colleagues demonstrated, in early PsA but not in early rheumatoid arthritis (RA), peri-entheseal in¯ammation together with bonemarrow oedema maximal at entheseal insertions 5±7 . These ®ndings led them to propose that the synovitis of PsA is secondary to entheseal in¯ammation, whereas in RA synovitis is the primary event 8 . Since enthesitis is a frequent feature in many forms of spondyloarthropathy, they suggest that this is the`common thread' that unites this heterogeneous group of conditions. Their hypothesis is intriguing, but it does not explain why PsA itself can present with diverse patterns of joint involvement or why some forms of arthritis are ®brotic and non-erosive while others are highly destructive 9 .
The notion that PsA is a distinct disorder, rather than the fortuitous association of two common disorders (arthritis and psoriasis), is founded mainly on epidemiological studies 10 . Arthritis develops in some 5±7% of psoriatic patients, a rate much higher than would be predicted for a fortuitous association 5 . On the other hand, the onset of skin and joint lesions is synchronous in only 15% of cases: in 60% of patients the psoriasis precedes the arthritis while in 25% the reverse occurs. In a small proportion of patients PsA can be diagnosed even in the absence of skin psoriasis (PsA sine psoriasis) 6 . Furthermore, the relationship between skin and joint manifestations is rather loose in terms of both disease activity and temporal occurrence 6±8 . Patients with severe dermatitis may have mild arthritis, and vice versa, while arthritis can precede or follow dermatitis by several years. The main challenge for clinicians is how to distinguish those patients who are going to get severe articular disease and require aggressive treatment, from those who will have a milder form. Hence the need to establish prognostic factors.
PROGNOSTIC FACTORS
The most useful clinical/radiological predictors of progressive damage are a large number of joint effusions, heavy medication in the past 9 and the presence of radiological damage 10 . There is only a modest correlation between PsA and cutaneous or nail psoriasis in terms of disease activity 6, 7 . Absence of nail lesions is said to be a favourable sign 10 while some authorities still regard extensive skin involvement as possibly indicating a poor prognosis 11 . A particularly gloomy prognostic factor in PsA (and in the other spondyloarthropathies) is HIV carrier status. HIV infection not only enhances susceptibility to spondyloarthropathies but also strongly correlates with aggressive and sustained disease. HIV should be considered in all patients with fulminant PsA 4 . Conversely, the development of PsA or another rheumatic condition in a patient with HIV infection signi®es a poor outlook.
In PsA as in RA, genetic factors are likely to be important not only in predisposing to the development of disease but also in determining its severity. In a survey of patients followed up for several years, the HLA antigens B27, B39 and DQw3 were associated with more severe disease 12, 13 . In particular, B27 in the presence of DR7 and DQw3 in the absence of DR7 were predictors of disease progression through all stages, while HLA-B22 was protective. Other groups have reported an increased frequency of DR4 in patients with PsA who developed a symmetrical polyarthritis akin to RA. As in RA, the DR4 association was not con®rmed in a population of Italian PsA patients, whose genetic make-up differs from that of northern Europeans 14 .
At the bedside, the erythrocyte sedimentation rate (ESR), plasma C-reactive protein (CRP) and plasma ®brinogen all correlate with clinical disease activity. A low ESR points to a favourable prognosis 9 , a persistently high ESR to increased risk of death 10 . In patients with early (56 months) monoarticular disease, a correlation was found between synovial¯uid interleukin (IL)-1b levels and the number of affected joints after three years 15 . In contrast, neither the ESR nor the CRP proved capable of predicting the evolution of monoarticular PsA to polyarthritis. Normal serum levels of the soluble IL-2R (s-IL-2R) and of the RANTES chemokines were associated with good outcome in PsA patients treated with cyclosporin. Thus, baseline determination of these mediators can help identify the responders to cyclosporin, although we do not know whether normal serum s-IL-2R and RANTES levels at disease onset in themselves point to a favourable outcome Recently, our group found that amounts of synovial IL-10 mRNA were signi®cantly higher in patients with non-erosive forms of chronic arthropathies, including PsA, than in patients with erosive disease (Huizinga TWJ, Keijsers V, Yanaia G, et al., unpublished). These data indicate that IL-10 may protect against erosion of cartilage and bone, a concept supported by the analysis of a cohort of 138 women with RA followed up for 12 years. Patients expressing the 71082 AA IL-10 polymorphism (associated with high IL-10 production) had a lower Sharp score for radiological damage than those expressing the 71082 GG allele (associated with low IL-10 production). Probably, therefore, the evolution of the various forms of PsA is in¯uenced by the balance between destructive cytokines (such as tumour necrosis factor, IL-1 and IL-6) and reparative cytokines (IL-10, transforming growth factor, interferon-b).
CLINICAL FORMS OF PSA
Several attempts have been made to stratify patients according to the pattern of joint involvement. The advantage of this approach is that patients with homogeneous features can be compared more easily in epidemiological studies, while from a clinical point of view it can facilitate the recognition of disease evolution patterns within each subset. The most popular and long-established classi®cation criteria are those of Moll and Wright 16 , who distinguished ®ve clinical subgroups (see Box 1). This classi®cation is still in use today, but it does have drawbacks. First, although its speci®city is satisfactory, the sensitivity is quite low (about 61%) 17 . Part of the reason may be that this classi®cation does not include subsets of PsA that are now recognized, such as asymmetric polyarthritis 18 and isolated enthesopathy 19 . Secondly, the overlaps between the different subsets can result in inconsistencies in classifying patients. Thirdly, and perhaps most important, new data suggest that these subsets do not remain distinct over time but can evolve from one to another 7 . If the third point is correct they will be of little clinical use since no reliable correlations can be made between disease subgroups and evolution or outcome. According to a recent re-evaluation, only two subgroups seem clearly de®ned, one characterized by a predominant axial involvement (with or without peripheral arthritis) and one characterized by peripheral arthritis in the absence of axial disease 18 . These patterns are determined mainly on clinical grounds, but several features suggest that they represent genuinely different subsets within PsA. Axial disease, but not peripheral disease, is strongly associated with HLA-B27 and is relatively unresponsive to treatment with second-line agents such as sulphasalazine and methotrexate. Furthermore, peripheral joint disease may be more severe in patients with axial involvement. The major defect of this classi®cation is that sacro-iliac joint involvement may often be underrecognized, which explains to some extent why the ®gures for the proportion of PsA patients with axial involvement can vary considerably (30± 78% between studies) 20 .
PATHOGENESIS
Genetic mechanisms are believed important in the development of PsA since concordance in inheritance between monozygotic twins is considerably higher than in dizygotic twins 21 . Cutaneous psoriasis is associated with the HLA antigens Cw6, B17 and B13 (the two latter because of linkage disequilibrium with Cw6); PsA shows a much weaker association with the above antigens, merely re¯ecting the coexistence of psoriasis 21 . Nevertheless, some HLA associations with PsA are genuine. In particular, HLA B27 shows a strong correlation with the clinical subset characterized by prominent axial involvement and also with uveitis in PsA and other spondyloarthropathies. The subdivision of HLA-B16 (B38 and B39) was found to be associated with spinal disease and peripheral arthritis 21 . We have already mentioned that the frequency of DR4 is increased in PsA patients with polyarticular`RA-like' joint disease. Finally, outside the HLA locus, an increased frequency of a particular polymorphism for the switch region of the immunoglobulin heavy-chain genes was found in 61% of PsA patients but only 12.2% of patients with psoriasis alone. Therefore, PsA and psoriasis seem to be associated overall with different susceptibility genes.
Immunological to anti-T-cell therapies such as cyclosporin 22 . However, important differences suggest that skin and joint disease are mediated by different cells 23 : (a) the production of Th1type cytokines, such as IL-2 and interferon-g, is increased in the skin, but not in synovial samples; (b) analysis of TcR usage by paired skin and synovial samples revealed different oligoclonal patterns, suggesting that lymphocytes recognize different antigens in the two compartments; (c) T cells derived from psoriatic skin, when injected into severe combined immunode®cient (SCID) mice, can induce psoriasis in normal human skin grafted onto the SCID mice, but not arthritis in the animals; (d) T cells positive for the cutaneous lymphocytic antigen (CLA), the homing receptor for the lymphocyte subset that migrates preferentially to the skin, were shown by our group to accumulate in the skin, but not in paired synovial samples from patients with PsA 23 . Therefore, although there is no doubt that PsA and psoriasis are closely associated conditions, the pathogenic link remains at present elusive.
TREATMENT
The treatment of PsA is directed at combating psoriasis, arthritis, or both. Many patients with PsA who have mild synovitis respond well to non-steroidal anti-in¯ammatory drugs (NSAIDs) alone, while persistent monoarthritis is often improved by intra-articular steroid injections 8 . However, PsA patients with severe articular disease commonly need a combined treatment with NSAIDs and disease-modifying antirheumatic drugs (DMARDs). The DMARDs proposed for the treatment of PsA are numerous and largely overlap with those used in RA, though antimalarials and gold compounds are seldom used for fear they will exacerbate cutaneous psoriasis (the subset of patients with`RA-like' involvement seem to respond well to gold therapy 8 ). Sulphasalazine is reported in some 24 studies to bene®t both articular and cutaneous disease, but whether it can halt radiographic progression is doubtful 25 . The dosage of sulphasalazine may be important in determining clinical ef®cacy, lower doses being perhaps less effective in disease control. Methotrexate has an excellent safety and effectiveness pro®le at a`low' dosage (up to 15 mg per week) and is seen by many as the secondline agent of choice for patients unresponsive to NSAIDs 26 . However, methotrexate should not be used when renal function is impaired, and patients must avoid medications such as sulpha drugs and ketoconazole that can interact with it. Cyclosporin is also very effective in the treatment of psoriasis and arthritis 27 , but concerns about its renal toxicity even at the recommended low dose (3 mg/kg per day) limit its use to those patients unresponsive to other DMARDs 28 . Systemic steroids are best avoided because, even though they are highly effective, severe¯ares of disease, particularly the psoriasis, can follow discontinuation of treatment or even tapering of the dose. For patients who do not respond adequately to DMARD monotherapy, combined therapy with methotrexate and sulphasalazine, or with methotrexate and cyclosporin, has proved superior to methotrexate alone 29 . Although rheumatologists have been using these drugs for years on the basis of the above studies, the scarcity of adequately-sized randomized controlled trials stands in the way of evidence-based guidelines. The main reason lies in the heterogeneity of the disease and the consequent dif®culty in comparing homogeneous groups in suf®cient numbers. As for the future, some of the powerful new agents used to treat refractory RA may also be helpful in severe PsA. Anti-TNF therapy has been used for a decade now with satisfactory clinical results in most cases, although erosive disease may still progress 30 . Le¯unomide, a novel isoxazol derivative that inhibits lymphocyte activity by interfering with de-novo pyrimidine synthesis, has proved at least equal to other well-established DMARDs in terms of symptomatic control and possibly retardation of erosive disease 31 . At present, neither anti-TNF therapy nor le¯unomide is licensed for the treatment of PsA. Finally, in patients with mild articular disease but extensive cutaneous manifestations, the best options are therapies that selectively target the psoriasis, such as photochemotherapy (psoralen plus ultraviolet A) or, in resistant cases, retinoids 32 . Recently, vitamin D derivatives (1,25-dihydroxyvitamin D3) have been shown to ameliorate articular and particularly cutaneous manifestations, but the safety and effectiveness of these agents has not been clearly established 33 .
Thus, in PsA it is important to tailor the treatment to the severity of the disease. Unfortunately, there is often dif®culty in judging at disease onset, on clinical grounds alone, whether a patient will develop a destructive or a mild arthropathy.
